Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.61 |
| ▸ | NPC1 | O15118 | 6/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.61 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 7/20 | 0.55 |
| ▸ | MEN1 | O00255 | 5/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.51 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ELANE | P08246 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7108085 | 0.82 | KMT2A (0.62) | RAB9ANPC1SMN1; SMN2MAPTMEN1 | |
| SCHEMBL9641204 | 0.80 | RAB9A (0.56) | RAB9ANPC1SMN1; SMN2DAGLAMAPT | |
| SCHEMBL12394351 | 0.80 | RAB9A (0.60) | RAB9ANPC1SMN1; SMN2DAGLAMAPT | |
| SCHEMBL3575249 | 0.80 | MEN1 (0.57) | RAB9ANPC1SMN1; SMN2DAGLAMAPT | |
| SCHEMBL2353937 | 0.80 | RAB9A (0.56) | RAB9ANPC1SMN1; SMN2DAGLAMAPT | |
| SCHEMBL3758564 | 0.80 | RAB9A (0.56) | RAB9ANPC1SMN1; SMN2DAGLAMAPT | |
| SCHEMBL8139921 | 0.80 | RAB9A (0.56) | RAB9ANPC1SMN1; SMN2DAGLAMAPT | |
| SCHEMBL31312575 | 0.78 | ALDH1A1 (0.60) | RAB9ANPC1SMN1; SMN2DAGLAMAPT | |
| SCHEMBL7109163 | 0.77 | RAB9A (0.52) | RAB9ANPC1SMN1; SMN2DAGLAMAPT | |
| SCHEMBL30358395 | 0.77 | RAB9A (0.53) | RAB9ANPC1SMN1; SMN2DAGLAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | SUMMIT (OXFORD) LIMITED (GB) | 2011-08-11 | — | — | US | claimed |
| EP-3251694-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit (Oxford) Limited (GB) | 2017-12-06 | — | — | EP | disclosed |
| EP-2170396-B1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORP PLC (GB) | 2016-12-21 | — | — | EP | disclosed |
| EP-1986633-B1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORP PLC (GB) | 2014-07-30 | — | — | EP | disclosed |
| US-20140018320-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2014-01-16 | — | — | US | disclosed |
| US-20140011782-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2014-01-09 | — | — | US | disclosed |
| US-8518980-B2 | Treatment of Duchenne muscular dystrophy | SUMMIT CORPORATION PLC (GB) | 2013-08-27 | — | — | US | disclosed |
| US-8501713-B2 | Drug combinations for the treatment of duchenne muscular dystrophy | SUMMIT CORPORATION PLC (GB) | 2013-08-06 | — | — | US | disclosed |
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | SUMMIT (OXFORD) LIMITED (GB) | 2011-08-11 | — | — | US | disclosed |
| EP-2176246-A2 | POLYMORPHS OF A COMPOUND FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | BioMarin IGA Limited (BS) | 2010-04-21 | — | — | EP | disclosed |
| EP-2170396-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | BioMarin IGA Limited (BS) | 2010-04-07 | — | — | EP | disclosed |
| US-20090075938-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT (OXFORD) LIMITED (GB) | 2009-03-19 | — | — | US | disclosed |
| US-20090048314-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2009-02-19 | — | — | US | disclosed |
| WO-2009021748-A2 | POLYMORPHS OF A COMPOUND FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2009-02-19 | — | — | WO | disclosed |
| WO-2009019504-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2009-02-12 | — | — | WO | disclosed |
| EP-1986633-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit Corporation Plc (GB) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007091106-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | PYGM, CPT1B, GYS1 | RAB9A 3748/4885NPC1 2477/4885SMN1; SMN2 4/4885 |
| US-20140011782-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | PYGM, CPT1B, GYS1 | RAB9A 3748/4885NPC1 2477/4885SMN1; SMN2 4/4885 |
| US-20140018320-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | NR0B1, NR0B2, NR3C1 | RAB9A 4325/4885NPC1 3637/4885SMN1; SMN2 9/4885 |
| US-20090048314-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | UTRN, SMN1; SMN2, MTPN | RAB9A 4004/4885NPC1 3291/4885SMN1; SMN2 2/4885 |
| US-20090075938-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | NR0B1, NR0B2, NR3C1 | RAB9A 4325/4885NPC1 3637/4885SMN1; SMN2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.